Immunogenic cell death

International Journal of Developmental Biology

Volumn 59, Issue 1-3, 2015, Pages 131-140

  Garg, Abhishek D ^a   Dudek Peric, Aleksandra M ^a   Romano, Erminia ^a   Agostinis, Patrizia ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

Antigen; Cancer; Chemotherapy; Damage associated molecular patterns; Danger signalling; Danger signals; ER stress; Immunogenic cell death; Immunogenicity; Photodynamic therapy (PDT)

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CALRETICULIN; CHAPERONE; CLOSTRIDIUM DIFFICILE TOXIN B; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HYPERICIN; IDARUBICIN; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; REACTIVE OXYGEN METABOLITE; SHIKONIN; TUMOR NECROSIS FACTOR; VORINOSTAT; WOGONIN; CANCER ANTIBODY; CANCER VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; BENIGN TUMOR; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; DOWN REGULATION; ENDOPLASMIC RETICULUM; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TUMOR IMMUNITY; APOPTOSIS; DRUG EFFECTS; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR ESCAPE;

ANTIBODIES, NEOPLASM; APOPTOSIS; CANCER VACCINES; HUMANS; IMMUNOLOGIC SURVEILLANCE; NEOPLASMS; TUMOR ESCAPE;

EID: 84940650524     PISSN: 02146282     EISSN: 16963547     Source Type: Journal    
DOI: 10.1387/ijdb.150061pa     Document Type: Article

References (94)

1. ADKINS, I., FUCIKOVA, J., GARG, A.D., AGOSTINIS, P. and SPISEK, R. (2014). Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 3: e968434.
2. APETOH, L., GHIRINGHELLI, F., TESNIERE, A., CRIOLLO, A., ORTIZ, C., LIDEREAU, R., MARIETTE, C., CHAPUT, N., MIRA, J.P., DELALOGE, S. et al., (2007a). The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220: 47-59.
3. APETOH, L., GHIRINGHELLI, F., TESNIERE, A., OBEID, M., ORTIZ, C., CRIOLLO, A., MIGNOT, G., MAIURI, M.C., ULLRICH, E., SAULNIER, P. et al., (2007b). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059.
4. BEHRENS, M.D., WAGNER, W.M., KRCO, C.J., ERSKINE, C.L., KALLI, K.R., KREMPSKI, J., GAD, E.A., DISIS, M.L. and KNUTSON, K.L. (2008). The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 111: 1472-1479.
5. BOON, T. and KELLERMANN, O. (1977). Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci USA 74: 272-275.
6. BOON, T. and VAN PEL, A. (1978). Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci USA 75: 1519-1523.
7. BUGAUT, H., BRUCHARD, M., BERGER, H., DERANGERE, V., ODOUL, L., EUVRARD, R., LADOIRE, S., CHALMIN, F., VEGRAN, F., REBE, C. et al., (2013). Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic immunogenic cell death and proliferation of regulatory T cells. PLoS One 8: e65181.
8. CASARES, N., PEQUIGNOT, M.O., TESNIERE, A., GHIRINGHELLI, F., ROUX, S., CHAPUT, N., SCHMITT, E., HAMAI, A., Hervas-Stubbs, S., OBEID, M. et al., (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701.
9. CHANG, M.K., BINDER, C.J., MILLER, Y.I., SUBBANAGOUNDER, G., SILVERMAN, G.J., BERLINER, J.A. and WITZTUM, J.L. (2004). Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 200: 1359-1370.
10. CHAO, M.P., JAISWAL, S., Weissman-Tsukamoto, R., ALIZADEH, A.A., GENTLES, A.J., VOLKMER, J., WEISKOPF, K., WILLINGHAM, S.B., RAVEH, T., PARK, C.Y. et al., (2010). Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2: 63-94.
11. CHEN, H.M., WANG, P.H., CHEN, S.S., WEN, C.C., CHEN, Y.H., YANG, W.C. and YANG, N.S. (2012). Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol Immunother 61: 1989-2002.
12. CHIANG, C.L., LEDERMANN, J.A., AITKENS, E., BENJAMIN, E., KATZ, D.R. and CHAIN, B.M. (2008). Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 14: 4898-4907.
13. CHIBA, S., BAGHDADI, M., AKIBA, H., YOSHIYAMA, H., KINOSHITA, I., Dosaka-Akita, H., FUJIOKA, Y., OHBA, Y., GORMAN, J.V., COLGAN, J.D. et al., (2012). Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 13: 832-842.
14. CIAMPRICOTTI, M., HAU, C.S., DOORNEBAL, C.W., JONKERS, J. and DE VISSER, K.E. (2012). Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med 18: 344-346.
15. COULIE, P.G., VAN DEN EYNDE, B.J., VAN DER BRUGGEN, P. and BOON, T. (2014). Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14: 135-146.
16. DE PLAEN, E., LURQUIN, C., VAN PEL, A., MARIAME, B., SZIKORA, J.P., WOLFEL, T., SIBILLE, C., CHOMEZ, P. and BOON, T. (1988). Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci USA 85: 2274-2278.
17. DUDEK, A.M., GARG, A.D., KRYSKO, D.V., DE RUYSSCHER, D. and AGOSTINIS, P. (2013). Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 24: 319-333.
18. Dudek-Peric AM, FERREIRA GB, MUCHOWICZ A, WOUTERS J, PRADA N, MARTIN S, et al. (2015). Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 75: 1603-1614.
19. DUEWELL, P., STEGER, A., LOHR, H., BOURHIS, H., HOELZ, H., KIRCHLEITNER, S.V., STIEG, M.R., GRASSMANN, S., KOBOLD, S., SIVEKE, J.T. et al., (2014). RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8 T cells. Cell Death Differ 21: 1825-1837.
20. DUNN, G.P., BRUCE, A.T., IKEDA, H., OLD, L.J. and SCHREIBER, R.D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
21. ELLIOTT, M.R., CHEKENI, F.B., TRAMPONT, P.C., LAZAROWSKI, E.R., KADL, A., WALK, S.F., PARK, D., WOODSON, R.I., OSTANKOVICH, M., SHARMA, P. et al., (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461: 282-286.
22. FUCIKOVA, J., KRALIKOVA, P., FIALOVA, A., BRTNICKY, T., ROB, L., BARTUNKOVA, J. and SPISEK, R. (2011). Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 71: 4821-4833.
23. FUCIKOVA, J., MOSEROVA, I., TRUXOVA, I., HERMANOVA, I., VANCUROVA, I., PARTLOVA, S., FIALOVA, A., SOJKA, L., CARTRON, P.F., HOUSKA, M. et al., (2014). High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 135: 1165-1177.
24. FUCIKOVA J, MOSEROVA I, URBANOVA L, BEZU L, KEPP O, CREMER I, SALEK C, STRNAD P, KROEMER G, GALLUZZI L and SPISEK R (2015). Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front. Immunol. 6: 402. (doi: 10.3389/fimmu.2015.00402).
25. GALLUZZI, L., KEPP, O. and KROEMER, G. (2012). Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J 31: 1055-1057.
26. GALLUZZI, L., KEPP, O. and KROEMER, G. (2013). Immunogenic cell death in radiation therapy. Oncoimmunology 2: e26536.
27. GALLUZZI, L., VACCHELLI, E., Bravo-San pedro, J.M., BUQUE, A., SENOVILLA, L., BARACCO, E.E., BLOY, N., CASTOLDI, F., ABASTADO, J.P., AGOSTINIS, P. et al., (2014). Classification of current anticancer immunotherapies. Oncotarget 5: 12472-12508.
28. GAMEIRO, S.R., JAMMEH, M.L., WATTENBERG, M.M., TSANG, K.Y., FERRONE, S. and HODGE, J.W. (2014). Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 5: 403-416.
29. GARDAI, S.J., MCPHILLIPS, K.A., FRASCH, S.C., JANSSEN, W.J., STAREFELDT, A., Murphy-Ullrich, J.E., BRATTON, D.L., OLDENBORG, P.A., MICHALAK, M. and HENSON, P.M. (2005). Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123: 321-334.
30. GARG, A.D. and AGOSTINIS, P. (2014). ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. Photochem Photobiol Sci 13: 474-487.
31. GARG, A.D., DUDEK, A.M. and AGOSTINIS, P. (2013a). Calreticulin surface exposure is abrogated in cells lacking, chaperone-mediated autophagy-essential gene, LAMP2A. Cell Death Dis 4: e826.
32. GARG, A.D., DUDEK, A.M. and AGOSTINIS, P. (2013b). Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 39: 355-367.
33. GARG, A.D., DUDEK, A.M., FERREIRA, G.B., VERFAILLIE, T., VANDENABEELE, P., KRYSKO, D.V., MATHIEU, C. and AGOSTINIS, P. (2013c). ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 9: 1292-1307.
34. GARG, A.D., KRYSKO, D.V., VANDENABEELE, P. and AGOSTINIS, P. (2012a). The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology 1: 786-788.
35. GARG, A.D., KRYSKO, D.V., VANDENABEELE, P. and AGOSTINIS, P. (2012b). Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 61: 215-221.
36. GARG, A.D., KRYSKO, D.V., VERFAILLIE, T., KACZMAREK, A., FERREIRA, G.B., MARYSAEL, T., RUBIO, N., FIRCZUK, M., MATHIEU, C., ROEBROEK, A.J. et al., (2012c). A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 31: 1062-1079.
37. GARG, A.D., MARTIN, S., GOLAB, J. and AGOSTINIS, P. (2014). Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 21: 26-38.
38. GARRIDO, G., RABASA, A., SANCHEZ, B., LOPEZ, M.V., BLANCO, R., LOPEZ, A., HERNANDEZ, D.R., PEREZ, R. and FERNANDEZ, L.E. (2011). Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 187: 4954-4966.
39. GHIRINGHELLI, F., APETOH, L., TESNIERE, A., AYMERIC, L., MA, Y., ORTIZ, C., VERMAELEN, K., PANARETAKIS, T., MIGNOT, G., ULLRICH, E. et al., (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178.
40. GOPAL, U., BOHONOWYCH, J.E., Lema-Tome, C., LIU, A., Garrett-Mayer, E., WANG, B. and ISAACS, J.S. (2011). A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS One 6: e17649.
41. GREGORY, C.D. and BROWN, S.B. (2005). Apoptosis: eating sensibly. Nat Cell Biol 7: 1161-1163.
42. GUPTA, S., MCGRATH, B. and CAVENER, D.R. (2010). PERK (EIF2AK3) regulates proinsulin trafficking and quality control in the secretory pathway. Diabetes 59: 1937-1947.
43. HEWITT, H.B., BLAKE, E.R. and WALDER, A.S. (1976). A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 33: 241-259.
44. HU, D.E., MOORE, A.M., THOMSEN, L.L. and BRINDLE, K.M. (2004). Uric acid promotes tumor immune rejection. Cancer Res 64: 5059-5062.
45. JOHANSEN, M.L. and BROWN, E.J. (2007). Dual regulation of SIRPalpha phosphorylation by integrins and CD47. J Biol Chem 282: 24219-24230.
46. JUBE, S., RIVERA, Z., BIANCHI, M.E., POWERS, A., WANG, E., PAGANO, I.S., PASS, H.I., GAUDINO, G., CARBONE, M. and YANG, H. (2012). Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 72: 3290-3
47. KARIKO, K., NI, H., CAPODICI, J., LAMPHIER, M. and WEISSMAN, D. (2004). mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279: 12542-12550.
48. KEPP, O., SENOVILLA, L., VITALE, I., VACCHELLI, E., ADJEMIAN, S., AGOSTINIS, P., APETOH, L., ARANDA, F., BARNABA, V., BLOY, N. et al., (2014). Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3: e955691.
49. KOKS, C.A., GARG, A.D., EHRHARDT, M., RIVA, M., VANDENBERK, L., BOON, L., VLEESCHOUWER, S.D., AGOSTINIS, P., GRAF, N. and VAN GOOL, S.W. (2015). Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 136: E313-E325.
50. KROEMER, G., GALLUZZI, L., KEPP, O. and ZITVOGEL, L. (2013). Immunogenic cell death in cancer therapy. Annu Rev Immunol 31: 51-72.
51. KRYSKO, D.V., AGOSTINIS, P., KRYSKO, O., GARG, A.D., BACHERT, C., LAMBRECHT, B.N. and VANDENABEELE, P. (2011). Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 32: 157-164.
52. KRYSKO, D.V., GARG, A.D., KACZMAREK, A., KRYSKO, O., AGOSTINIS, P. and VANDENABEELE, P. (2012). Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12: 860-875.
53. MA, Y., ADJEMIAN, S., MATTAROLLO, S.R., YAMAZAKI, T., AYMERIC, L., YANG, H., PORTELA CATANI, J.P., HANNANI, D., DURET, H., STEEGH, K. et al., (2013). Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38: 729-741.
54. MA, Y., AYMERIC, L., LOCHER, C., MATTAROLLO, S.R., DELAHAYE, N.F., PEREIRA, P., BOUCONTET, L., APETOH, L., GHIRINGHELLI, F., CASARES, N. et al., (2011). Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208: 491-503.
55. MARTIN, S., Dudek-Peric, A.M., MAES, H., GARG, A.D., GABRYSIAK, M., DEMIRSOY, S., SWINNEN, J.V. and AGOSTINIS, P. (2015). Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Biochem Pharmacol 93: 290-304.
56. MARTINON, F., PETRILLI, V., MAYOR, A., TARDIVEL, A. and TSCHOPP, J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
57. MARTINS, I., KEPP, O., SCHLEMMER, F., ADJEMIAN, S., TAILLER, M., SHEN, S., MICHAUD, M., MENGER, L., GDOURA, A., TAJEDDINE, N. et al., (2011). Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30: 1147-1158.
58. MARTINS, I., WANG, Y., MICHAUD, M., MA, Y., SUKKURWALA, A.Q., SHEN, S., KEPP, O., METIVIER, D., GALLUZZI, L., PERFETTINI, J.L. et al., (2014). Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 21: 79-91.
59. MATTAROLLO, S.R., LOI, S., DURET, H., MA, Y., ZITVOGEL, L. and SMYTH, M.J. (2011). Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 71: 4809-4820.
60. MATZINGER, P. (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
61. MENGER, L., VACCHELLI, E., ADJEMIAN, S., MARTINS, I., MA, Y., SHEN, S., YAMAZAKI, T., SUKKURWALA, A.Q., MICHAUD, M., MIGNOT, G. et al., (2012). Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 4: 143-199.
62. MICHAUD, M., MARTINS, I., SUKKURWALA, A.Q., ADJEMIAN, S., MA, Y., PELLEGATTI, P., SHEN, S., KEPP, O., SCOAZEC, M., MIGNOT, G. et al., (2011). Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334: 1573-1577.
63. OBEID, M., TESNIERE, A., GHIRINGHELLI, F., FIMIA, G.M., APETOH, L., PERFETTINI, J.L., CASTEDO, M., MIGNOT, G., PANARETAKIS, T., CASARES, N. et al., (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
64. PALUMBO, R., SAMPAOLESI, M., DE MARCHIS, F., TONLORENZI, R., COLOMBETTI, S., MONDINO, A., COSSU, G. and BIANCHI, M.E. (2004). Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164: 441-449.
65. PANARETAKIS, T., KEPP, O., BROCKMEIER, U., TESNIERE, A., BJORKLUND, A.C., CHAPMAN, D.C., DURCHSCHLAG, M., JOZA, N., PIERRON, G., VAN ENDERT, P. et al., (2009). Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28: 578-590.
66. PAWARIA, S. and BINDER, R.J. (2011). CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun 2: 521.
67. PENG, R.Q., CHEN, Y.B., DING, Y., ZHANG, R., ZHANG, X., YU, X.J., ZHOU, Z.W., ZENG, Y.X. and ZHANG, X.S. (2010). Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol 16: 2428-2434.
68. POL, J., BLOY, N., OBRIST, F., EGGERMONT, A., GALON, J., CREMER, I., ERBS, P., LIMACHER, J.-M., PREVILLE, X., ZITVOGEL, L. et al., (2014). Trial Watch: Oncolytic viruses for cancer therapy. Oncoimmunology 3: 28694.
69. PRADEU, T. and COOPER, E.L. (2012). The danger theory: 20 years later. Front Immunol 3: 287.
70. Satpute-Krishnan, P., AJINKYA, M., BHAT, S., ITAKURA, E., HEGDE, R.S. and Lippincott-Schwartz, J. (2014). ER stress-induced clearance of misfolded GPI-anchored proteins via the secretory pathway. Cell 158: 522-533.
71. SCHIAVONI, G., SISTIGU, A., VALENTINI, M., MATTEI, F., SESTILI, P., SPADARO, F., SANCHEZ, M., LORENZI, S., D’URSO, M.T., BELARDELLI, F. et al., (2011). Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 71: 768-778.
72. SCHILDKOPF, P., FREY, B., OTT, O.J., RUBNER, Y., MULTHOFF, G., SAUER, R., FIETKAU, R. and GAIPL, U.S. (2011). Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother Oncol 101: 109-115.
73. SENOVILLA, L., VITALE, I., MARTINS, I., TAILLER, M., PAILLERET, C., MICHAUD, M., GALLUZZI, L., ADJEMIAN, S., KEPP, O., Niso-Santano, M. et al., (2012). An immunosurveillance mechanism controls cancer cell ploidy. Science 337: 1678-1684.
74. SONG, S., ZHOU, F., CHEN, W.R. and XING, D. (2012). PDT-induced HSP70 externalization up-regulates NO production via TLR2 signal pathway in macrophages. FEBS Lett DOI: 10.1016/j.febslet.2012.11.026.
75. SPISEK, R., CHARALAMBOUS, A., MAZUMDER, A., VESOLE, D.H., JAGANNATH, S. and DHODAPKAR, M.V. (2007). Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109: 4839-4845.
76. SUKKURWALA, A.Q., ADJEMIAN, S., SENOVILLA, L., MICHAUD, M., SPAGGIARI, S., VACCHELLI, E., BARACCO, E.E., GALLUZZI, L., ZITVOGEL, L., KEPP, O. et al., (2014a). Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology 3: e28473.
77. SUKKURWALA, A.Q., MARTINS, I., WANG, Y., SCHLEMMER, F., RUCKENSTUHL, C., DURCHSCHLAG, M., MICHAUD, M., SENOVILLA, L., SISTIGU, A., MA, Y. et al., (2014b). Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ 21: 59-68.
78. SUZUKI, S. and KULKARNI, A.B. (2010). Extracellular heat shock protein HSP90beta secreted by MG63 osteosarcoma cells inhibits activation of latent TGF-beta1. Biochem Biophys Res Commun 398: 525-531.
79. VACCHELLI, E., EGGERMONT, A., Sautes-Fridman, C., GALON, J., ZITVOGEL, L., KROEMER, G. and GALLUZZI, L. (2013). Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2: e24612.
80. VAN DER BRUGGEN, P., TRAVERSARI, C., CHOMEZ, P., LURQUIN, C., DE PLAEN, E., VAN DEN EYNDE, B., KNUTH, A. and BOON, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
81. VAN PEL, A. and BOON, T. (1982). Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 79: 4718-4722.
82. WANG, C.M., PLOIA, C., ANSELMI, F., SARUKHAN, A. and VIOLA, A. (2014). Adenosine triphosphate acts as a paracrine signaling molecule to reduce the motility of T cells. EMBO J 33: 1354-1364.
83. WANG, H.T., LEE, H.I., GUO, J.H., CHEN, S.H., LIAO, Z.K., HUANG, K.W., TORNG, P.L. and HWANG, L.H. (2012). Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of immunotherapy by up-regulating the endothelial expression of adhesion molecules. Int J Cancer 130: 2892-2902.
84. WEMEAU, M., KEPP, O., TESNIERE, A., PANARETAKIS, T., FLAMENT, C., DE BOTTON, S., ZITVOGEL, L., KROEMER, G. and CHAPUT, N. (2010). Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 1: e104.
85. WEST, A.C., MATTAROLLO, S.R., SHORTT, J., CLUSE, L.A., CHRISTIANSEN, A.J., SMYTH, M.J. and JOHNSTONE, R.W. (2013). An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res 73: 7265-7276.
86. WONG, D.Y., ONG, W.W., and ANG, W.H. (2015). Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes. Angew.Chem. Int.Ed. 54: 6483-6487.
87. YANG, Y., LI, X.J., CHEN, Z., ZHU, X.X., WANG, J., ZHANG, L.B., QIANG, L., MA, Y.J., LI, Z.Y., GUO, Q.L. et al., (2012). Wogonin induced calreticulin/annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK/AKT dependent manner. PLoS One 7: e50811.
88. YU, Z., GENG, J., ZHANG, M., ZHOU, Y., FAN, Q. and CHEN, J. (2014). Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death. Oncotarget 5: 6526-6539.
89. ZAMARIN, D., HOLMGAARD, R.B., SUBUDHI, S.K., PARK, J.S., MANSOUR, M., PALESE, P., MERGHOUB, T., WOLCHOK, J.D. and ALLISON, J.P. (2014). Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. Sci. Translat. Med. 6: 226-32.
90. ZAPPASODI, R., PUPA, S.M., GHEDINI, G.C., BONGARZONE, I., MAGNI, M., CABRAS, A.D., COLOMBO, M.P., Carlo-Stella, C., GIANNI, A.M. and DI NICOLA, M. (2010). Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 70: 9062-9072.
91. ZHANG, H.M., DAI, H., HANSON, P.J., LI, H., GUO, H., YE, X., HEMIDA, M.G., WANG, L., TONG, Y., QIU, Y. et al., (2014). Antiviral activity of an isatin derivative via induction of PERK-Nrf2-mediated suppression of cap-independent translation. ACS Chem Biol 9: 1015-1024.
92. ZHU, X.M., YAO, Y.M., LIANG, H.P., XU, C.T., DONG, N., YU, Y. and SHENG, Z.Y. (2011). High mobility group box-1 protein regulate immunosuppression of regulatory T cells through toll-like receptor 4. Cytokine 54: 296-304.
93. ZITVOGEL, L., KEPP, O. and KROEMER, G. (2010). Decoding cell death signals in inflammation and immunity. Cell 140: 798-804.
94. ZITVOGEL, L., TESNIERE, A. and KROEMER, G. (2006). Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727.